Lab
U S Lab & Radiology LLC
U S Lab & Radiology LLC was paid $6.73M by Medicaid between Jan 2018 and Dec 2024, across 168 billing codes. Its largest line is P9604, Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge — 18% of everything it billed.
33Billing provider infoU S LAB & RADIOLOGY LLC
BROCKTON, MA 02301
BROCKTON, MA 02301
33aNPI1659322360assigned 05/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$6.73M
24GClaims3,480,737
24DCodes billed168
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Massachusetts
Rank by total paid#10 of 63
Median peer was paid$473K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUOMO, BRIAN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 714,161 | $1.32M | |
| 2019 | 679,932 | $1.25M | |
| 2020 | 533,313 | $1.16M | |
| 2021 | 466,854 | $916K | |
| 2022 | 415,982 | $789K | |
| 2023 | 378,036 | $729K | |
| 2024incomplete | 292,459 | $558K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 18% | 414,417 | 225,876 | $1.18M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 11% | 301,955 | 203,754 | $707K |
| 80048 | Basic metabolic panel (calcium, ionized) | 5.3% | 228,803 | 152,745 | $358K |
| 80053 | Comprehensive metabolic panel | 4.9% | 170,209 | 136,399 | $331K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.6% | 72,912 | 68,051 | $307K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 26,100 | 24,909 | $222K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.2% | 78,826 | 74,463 | $216K |
| ATP14 | 2.8% | 79,809 | 65,786 | $185K | |
| ATP08 | 2.7% | 127,677 | 88,472 | $180K | |
| 36415 | Collection of venous blood by venipuncture | 2.7% | 237,573 | 122,924 | $179K |
| 85027 | 2.2% | 82,188 | 68,178 | $145K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 5,366 | 3,176 | $143K |
156 more codes
| 83880 | 2.1% | 17,717 | $139K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 3,552 | $130K |
| 85610 | 1.9% | 147,016 | $130K | |
| 82607 | 1.8% | 27,563 | $118K | |
| 87088 | 1.7% | 65,299 | $117K | |
| 86141 | 1.7% | 17,191 | $114K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 61,068 | $110K |
| 80061 | Lipid panel | 1.6% | 55,973 | $107K |
| 80164 | 1.5% | 25,808 | $98K | |
| 80202 | 1.4% | 10,367 | $95K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 1.4% | 436,745 | $93K |
| 87631 | 1.1% | 1,882 | $75K | |
| 82746 | 1.0% | 15,289 | $69K | |
| 83735 | <1% | 24,309 | $53K | |
| 84439 | <1% | 18,750 | $50K | |
| 82140 | <1% | 6,855 | $48K | |
| 80050 | General health panel | <1% | 5,345 | $47K |
| 81001 | <1% | 62,539 | $44K | |
| 82728 | <1% | 10,145 | $43K | |
| 87186 | <1% | 23,970 | $42K | |
| 84134 | <1% | 8,463 | $38K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,932 | $38K |
| ATP15 | <1% | 12,654 | $36K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 268,964 | $33K |
| 80177 | <1% | 7,200 | $30K | |
| 83970 | <1% | 2,424 | $30K | |
| 80185 | <1% | 7,600 | $29K | |
| 80076 | <1% | 17,166 | $28K | |
| ATP17 | <1% | 12,415 | $27K | |
| 85652 | <1% | 17,450 | $25K | |
| 87493 | <1% | 3,711 | $25K | |
| 83540 | <1% | 12,917 | $25K | |
| 87536 | <1% | 362 | $23K | |
| 87077 | <1% | 13,559 | $23K | |
| 84153 | <1% | 2,727 | $18K | |
| 82248 | <1% | 18,429 | $18K | |
| 83550 | <1% | 7,671 | $18K | |
| 87040 | <1% | 3,652 | $16K | |
| ATP07 | <1% | 7,408 | $13K | |
| 84436 | <1% | 5,132 | $12K | |
| 84146 | <1% | 738 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 565 | $11K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 130 | $10K |
| 85007 | <1% | 9,254 | $10K | |
| 87071 | <1% | 3,353 | $10K | |
| ATP18 | <1% | 4,087 | $9K | |
| 80178 | <1% | 4,158 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,416 | $9K |
| 80156 | <1% | 2,504 | $9K | |
| ATP03 | <1% | 7,905 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 971 | $9K |
| 84480 | <1% | 1,605 | $8K | |
| ATP09 | <1% | 4,208 | $8K | |
| 85004 | <1% | 7,495 | $8K | |
| 80162 | <1% | 2,746 | $8K | |
| 80184 | <1% | 2,005 | $8K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 393 | $7K |
| 84132 | <1% | 6,117 | $7K | |
| 83690 | <1% | 3,007 | $7K | |
| 84100 | <1% | 8,051 | $7K | |
| 84479 | <1% | 2,863 | $7K | |
| 80159 | <1% | 748 | $6K | |
| 80175 | <1% | 1,684 | $6K | |
| 84550 | <1% | 7,566 | $6K | |
| 87184 | <1% | 3,284 | $6K | |
| 82150 | <1% | 2,629 | $5K | |
| 85018 | <1% | 10,225 | $5K | |
| 87205 | <1% | 3,722 | $5K | |
| ATP11 | <1% | 3,660 | $5K | |
| 85014 | <1% | 9,443 | $5K | |
| ATP10 | <1% | 3,254 | $5K | |
| 84466 | <1% | 1,243 | $5K | |
| 82565 | <1% | 6,337 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 391 | $4K |
| 84520 | <1% | 5,225 | $4K | |
| 85048 | <1% | 8,260 | $4K | |
| 82550 | <1% | 2,702 | $4K | |
| 80074 | <1% | 118 | $4K | |
| 80051 | <1% | 3,022 | $3K | |
| ATP16 | <1% | 942 | $3K | |
| 87899 | <1% | 1,030 | $3K | |
| 82040 | <1% | 4,089 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 120 | $3K |
| 84145 | <1% | 495 | $3K | |
| 87521 | Neg quan hep c or qual rna | <1% | 177 | $3K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 35 | $3K |
| 84295 | <1% | 2,679 | $3K | |
| 82570 | <1% | 1,730 | $3K | |
| 86769 | <1% | 151 | $3K | |
| 83721 | <1% | 1,658 | $3K | |
| 85379 | <1% | 829 | $3K | |
| 84481 | <1% | 555 | $2K | |
| 85730 | <1% | 881 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 136 | $2K |
| 86360 | <1% | 55 | $2K | |
| 84460 | <1% | 2,205 | $2K | |
| 87070 | <1% | 903 | $2K | |
| 82043 | <1% | 1,108 | $2K | |
| 84425 | <1% | 193 | $2K | |
| 85045 | <1% | 1,392 | $2K | |
| 80069 | <1% | 763 | $1K | |
| 86803 | <1% | 210 | $1K | |
| ATP02 | <1% | 1,282 | $1K | |
| 87045 | <1% | 484 | $1K | |
| 86592 | <1% | 641 | $1K | |
| 84450 | <1% | 1,948 | $1K | |
| 82310 | <1% | 1,059 | $1K | |
| 82947 | <1% | 3,046 | $1K | |
| 82553 | <1% | 133 | $925.11 | |
| 87081 | <1% | 600 | $766.26 | |
| 84484 | <1% | 244 | $698.35 | |
| 86361 | <1% | 32 | $684.54 | |
| 86355 | <1% | 55 | $682.00 | |
| 86359 | <1% | 55 | $682.00 | |
| 87015 | <1% | 460 | $648.81 | |
| 83615 | <1% | 773 | $637.22 | |
| 85049 | <1% | 355 | $549.13 | |
| 80183 | <1% | 79 | $539.23 | |
| ATP19 | <1% | 187 | $456.40 | |
| 86038 | <1% | 100 | $453.22 | |
| 84155 | <1% | 1,188 | $438.63 | |
| 87300 | <1% | 43 | $413.35 | |
| 82105 | <1% | 41 | $366.76 | |
| ATP04 | <1% | 301 | $345.34 | |
| 82784 | <1% | 68 | $338.09 | |
| 87147 | <1% | 224 | $336.59 | |
| 84075 | <1% | 384 | $306.00 | |
| 82977 | <1% | 338 | $302.80 | |
| 88112 | <1% | 16 | $273.06 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 83 | $244.54 |
| 87328 | <1% | 52 | $204.49 | |
| 87329 | <1% | 51 | $204.19 | |
| 84156 | <1% | 183 | $188.17 | |
| 80186 | <1% | 63 | $174.83 | |
| 87340 | <1% | 24 | $165.34 | |
| ATP13 | <1% | 124 | $163.35 | |
| 82330 | <1% | 31 | $140.68 | |
| 87177 | <1% | 59 | $134.47 | |
| 80197 | <1% | 39 | $130.43 | |
| ATP12 | <1% | 42 | $130.20 | |
| 86706 | <1% | 13 | $120.38 | |
| 86618 | <1% | 12 | $119.31 | |
| 82533 | <1% | 13 | $96.03 | |
| 87807 | <1% | 51 | $85.38 | |
| 87449 | <1% | 21 | $59.51 | |
| 83921 | <1% | 30 | $46.88 | |
| ATP06 | <1% | 15 | $32.32 | |
| 87299 | <1% | 22 | $28.04 | |
| 87279 | <1% | 21 | $21.95 | |
| 87276 | <1% | 21 | $21.45 | |
| 87260 | <1% | 21 | $19.56 | |
| 87280 | <1% | 21 | $18.94 | |
| 87275 | <1% | 21 | $18.25 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 63 | $16.05 |
| 84165 | <1% | 13 | $12.87 | |
| 82272 | <1% | 18 | $3.36 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUOMO, BRIAN (AUTHORIZED OFFICIAL/CFO)
| Provider | Location | Paid |
|---|---|---|
| Symphony Diagnostic Services No 1 LLC | Sparks, MD | $38.32M |
| Kan-Di-Ki LLC | North Hollywood, CA | $13.48M |
| New Schryver LLC | Denver, CO | $7.16M |
| Kan-Di-Ki LLC | Las Vegas, NV | $3.60M |
| Symphony Diagnostic Services No 1 LLC | Clearwater, FL | $3.22M |
| Community Mobile Diagnostics LLC | San Leandro, CA | $3.15M |
| New Schryver LLC | Denver, CO | $3.13M |
| American Diagnostics Services LLC | Windsor Mill, MD | $3.13M |
| Kan-Di-Ki, LLC | North Hollywood, CA | $784K |
| Kan-Di-Ki LLC | Tukwila, WA | $623K |
| New Schryver LLC | Carrollton, TX | $370K |
| Kan-Di-Ki LLC | Denver, CO | $289K |
| Kan-Di-Ki LLC | North Hollywood, CA | $274K |
| Kan-Di-Ki, LLC | Portland, OR | $268K |
| Kan-Di-Ki, LLC | Las Vegas, NV | $259K |
| Reono Bertagnolli a Medical Group | San Leandro, CA | $216K |
| Kan-Di-Ki, LLC | Phoenix, AZ | $144K |
| Kan Di Ki, LLC | Carrollton, TX | $92K |
| New Schryver LLC | Tukwila, WA | $83K |
| Community Mobile Ultrasound, LLC | Oceanside, CA | $73K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.